Shenzhen Chipscreen Biosciences Co. Ltd.SSE: 688321

Shareholders' Inquiry Transfer Plan

May 16, 2026 · Issued by Shenzhen Chipscreen Biosciences Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · May 16, 2026

On 6ix: 6ix.com/news/shareholders-inquiry-transfer-plan-23

Shareholders' Inquiry Transfer Plan

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix

Earlier from Shenzhen Chipscreen Biosciences

Announcement on Voluntary Disclosure of Approval of Chiglitazar Sodium for Market Release by the Pharmaceutical Administration Bureau, Macao SARMay 15
Announcement on Receipt of the "Decision on the Examination of an Invalidity Declaration Request" from the China National Intellectual Property AdministrationMay 9
Announcement on Adjusting the Conversion Price of "Chipscreen Convertible Bonds" Due to the Implementation of the 2025 Annual Profit Distribution and Resumption of Trading After Conversion SuspensionMay 8
Announcement on Convening the Q1 2026 Performance BriefingMay 1
Report for Q1 2026Apr 30

Later from Shenzhen Chipscreen Biosciences

Indicative Announcement on Pricing for Shareholders' Inquiry-based TransferMay 19
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer MultipleMay 23
Announcement on Progress in Repurchasing SharesJun 2
Announcement on Follow-up Credit Rating Results of "Chipscreen Convertible Bonds"Jun 27
Announcement on Conversion Result of Convertible Bonds and Share ChangesJul 2

All Shenzhen Chipscreen Biosciences news releases

Follow Shenzhen Chipscreen Biosciences into a list and get an email when it puts out news.

Follow Shenzhen Chipscreen Biosciences